Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Mimedx (MDXG) Operating Expenses (2016 - 2025)

Mimedx's Operating Expenses history spans 15 years, with the latest figure at -$131.8 million for Q4 2025.

  • For Q4 2025, Operating Expenses fell 168.48% year-over-year to -$131.8 million; the TTM value through Dec 2025 reached $65.0 million, down 66.32%, while the annual FY2025 figure was $71.6 million, 69.84% down from the prior year.
  • Operating Expenses for Q4 2025 was -$131.8 million at Mimedx, down from $119.6 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $192.5 million in Q4 2024 and bottomed at -$131.8 million in Q4 2025.
  • The 5-year median for Operating Expenses is $55.6 million (2022), against an average of $37.5 million.
  • The largest annual shift saw Operating Expenses crashed 350.48% in 2023 before it soared 270.41% in 2024.
  • A 5-year view of Operating Expenses shows it stood at $46.7 million in 2021, then dropped by 3.44% to $45.1 million in 2022, then plummeted by 350.48% to -$113.0 million in 2023, then skyrocketed by 270.41% to $192.5 million in 2024, then plummeted by 168.48% to -$131.8 million in 2025.
  • Per Business Quant, the three most recent readings for MDXG's Operating Expenses are -$131.8 million (Q4 2025), $119.6 million (Q3 2025), and $64.2 million (Q2 2025).